Description
Kamajoy-d
Kamajoy-d is a fixed-dose combination of sildenafil and dapoxetine. Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction, and dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) developed for premature ejaculation. The combination has been studied in men with both conditions, but the exact trade name Kamajoy-d itself could not be verified in official regulatory sources.
Active Ingredient and Medicine Class
Sildenafil belongs to the PDE5 inhibitor class. Dapoxetine is an SSRI. Together, they target two different sexual-function disorders: erectile dysfunction and premature ejaculation. Sildenafil is an approved medicine for erectile dysfunction in major regulatory sources, while dapoxetine is an approved medicine for premature ejaculation in some jurisdictions and is supported by clinical trial evidence.
Established Medical Uses
Sildenafil is established for the treatment of adult men with erectile dysfunction. Dapoxetine is established for the treatment of premature ejaculation in adult men. Published clinical studies have evaluated the combination in men who have both erectile dysfunction and premature ejaculation, with improvements reported in ejaculatory latency and erectile-function measures.
How It Works
Sildenafil works by enhancing the nitric oxide/cGMP pathway in penile tissue, which helps relax smooth muscle and improve blood flow needed for an erection. Dapoxetine increases serotonin activity by inhibiting serotonin reuptake, which can help delay ejaculation. The combination is intended to address both erection quality and ejaculation timing.
Important Safety Information
Sildenafil must not be used with nitrates or guanylate cyclase stimulators such as riociguat because of the risk of marked blood pressure lowering. It also requires caution with alpha-blockers and other medicines that can lower blood pressure. Dapoxetine has important interaction concerns with MAO inhibitors and other serotonergic medicines because of the risk of serotonin syndrome, and it may also be problematic in patients with conditions that predispose to fainting or orthostatic symptoms. Because this is a combination product, safety concerns from both components may apply.
Possible Side Effects
Commonly reported effects with sildenafil include headache, flushing, dyspepsia, nasal congestion, dizziness, visual changes, and palpitations. Dapoxetine commonly causes nausea, dizziness, headache, diarrhoea, somnolence, and insomnia. More serious adverse effects can include severe hypotension, syncope, priapism, and rare hypersensitivity reactions.
Scientific Evidence
Clinical evidence for the combination is limited but supportive in selected patients with coexisting erectile dysfunction and premature ejaculation. A phase III randomized study of dapoxetine in men already receiving a PDE5 inhibitor found improved ejaculatory latency and patient-reported outcomes versus placebo. A later open-label study of a sildenafil/dapoxetine combination also reported improved latency and erectile-function scores, with mostly mild and transient adverse events. Broader reviews suggest that combining an SSRI with a PDE5 inhibitor can improve premature-ejaculation outcomes, but the evidence base is still relatively small.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet or individual assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency — Viagra EPAR
- European Medicines Agency — Priligy referral
- Tuken et al. — Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction-DAP-SPEED Study — Int J Impot Res (2019)
- McMahon et al. — Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study — J Sex Med (2013)
